MarketPulse
U

$UTHR

5 articles found
5 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Transplants.org Launches AI-Powered Platform to Streamline Care for 103K+ Waiting Patients

New nonprofit Transplants.org launches AI-powered platform for organ transplant patients, backed by 25+ U.S. transplant centers, serving 103,000+ Americans awaiting transplants.
UTHRnonprofitorgan transplant
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

Interstitial Lung Disease Market Set to Surge 8.7% Annually Through 2036

Interstitial lung disease market valued at $6B in 2025 expected to grow 8.7% annually through 2036, driven by FDA-approved therapies and emerging pipeline candidates.
BMYCELGrRHHBYGSKUTHR+5FDA approvalclinical trials
BenzingaBenzinga··Piero Cingari

Powell Tamps Down Rate Hike Fears, Sending Markets Higher on Softer Inflation Outlook

U.S. stocks rally as Fed Chair Powell signals no imminent rate hikes and Trump discloses Iran negotiations, boosting equities across sectors.
BACBACpBBACpEBACpKBACpL+34stock marketfinancial stocks
BenzingaBenzinga··Vandana Singh

United Therapeutics Surges 16.5% on Positive Lung Disease Trial Results

United Therapeutics stock surges 16.5% after TETON-1 Phase 3 study shows Tyvaso meets primary endpoint in lung fibrosis treatment, with priority FDA review expected by summer 2026.
UTHRFDA approvalclinical trial
BenzingaBenzinga··Vandana Singh

United Therapeutics' Ralinepag Shows 55% Drop in PAH Worsening, Stock Soars

United Therapeutics ($UTHR) stock rallies 3.98% after Phase 3 trial shows ralinepag reduces PAH worsening 55%, with FDA filing targeted for mid-2026.
UTHRFDA approvalPhase 3 trial